For the fourth quarter of 2010, Lilly’s operating income was $1.45bn, compared to $1.21bn for the same period in 2009.
Eli Lilly has generated a net income of $1.17bn, compared to $915.4m for the same period in 2009.
For the full year of 2010, total revenue was $23.08bn, compared to $21.84bn for the same period in 2009.
Operating income was $6.53bn, compared to $5.59bn for the same period in 2009.
Net income was $5.07bn, compared to $4.33bn for the same period in 2009.
Eli Lilly chairman and CEO John Lechleiter said their fourth quarter results capped a year of solid financial performance in which they achieved volume-driven revenue growth along with good expense control.
"These results allowed us to deliver attractive earnings growth and a healthy dividend for our shareholders, while still investing in the research and development and business development activities that will enable us to bring the next generation of new medicines to patients," Lechleiter said.